Cellebrite DI (CLBT) Set to Announce Quarterly Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT – Get Rating) will be posting its quarterly earnings results before the market opens on Wednesday, May 10th. Analysts expect Cellebrite DI to post earnings of $0.03 per share for the quarter. Cellebrite DI has set its FY 2023 guidance at EPS.Investors that are interested in participating in the company's conference call can do so using this link.

Cellebrite DI (NASDAQ:CLBT – Get Rating) last released its quarterly earnings data on Wednesday, February 15th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. Cellebrite DI had a net margin of 44.63% and a return on equity of 34.28%. The business had revenue of $74.02 million during the quarter, compared to analyst estimates of $74.78 million. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $5.39 on Wednesday. The business has a fifty day moving average price of $5.77 and a 200-day moving average price of $5.08. The firm has a market capitalization of $1.02 billion, a P/E ratio of 8.84, a PEG ratio of 0.90 and a beta of 1.18. Cellebrite DI has a one year low of $3.80 and a one year high of $6.22.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Morgan Stanley boosted its holdings in shares of Cellebrite DI by 53,737.4% in the 4th quarter. Morgan Stanley now owns 2,144,884 shares of the company's stock valued at $9,352,000 after buying an additional 2,140,900 shares in the last quarter. Blair William & Co. IL grew its stake in Cellebrite DI by 3,021.1% in the 1st quarter. Blair William & Co. IL now owns 523,978 shares of the company's stock valued at $3,353,000 after acquiring an additional 507,190 shares during the period. State Street Corp increased its stake in shares of Cellebrite DI by 52.4% during the second quarter. State Street Corp now owns 236,821 shares of the company's stock worth $1,208,000 after purchasing an additional 81,381 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Cellebrite DI during the 4th quarter worth about $169,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Cellebrite DI by 159.3% in the first quarter. JPMorgan Chase & Co. now owns 49,499 shares of the company's stock valued at $317,000 after acquiring an additional 30,410 shares in the last quarter. 21.66% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of recent analyst reports. Needham & Company LLC increased their price target on shares of Cellebrite DI from $6.50 to $7.00 and gave the stock a "buy" rating in a report on Tuesday, March 14th. TheStreet upgraded shares of Cellebrite DI from a "d+" rating to a "c-" rating in a report on Friday, February 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Cellebrite DI presently has an average rating of "Moderate Buy" and an average target price of $8.60.

About Cellebrite DI

(Get Rating)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Featured Stories

• Get a free copy of the StockNews.com research report on Cellebrite DI (CLBT)
• Do Bank Stocks Go Up When Interest Rates Rise?
• How to Invest in Vertical Farming Stocks
• Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
• Ecolab: Slow And Steady Wins The Race
• MGM's Hot Hand Is All In For A Rally, After This Small Break

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.